Prime Medicine(NASDAQ) PRME

Market Cap$540.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-81%
5 YearN/A
1 Year-49%
1 Month-13%
Premium Feature
Moneyball Superscore
48/100
$3.22
+7.89%
+0.24Today
After hours$3.28+$0.07 (+2.02%)
Prime Medicine last closing stock price
MetricPriceDate
Last closeUSD 3.212026-10-05
Prime Medicine stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.65%USD 2.882026-09-28
1 month-13.24%USD 3.702026-09-04
3 month-19.55%USD 3.992026-07-07
Year to date-7.49%USD 3.472025-12-31
1 year-49.21%USD 6.322025-10-03
3 year-63.85%USD 8.882023-10-06
Since inception-80.61%USD 15.372022-10-20

Prime Medicine Financials at a Glance

Market Cap

$540.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.07

Net Income (TTM)

-$187.89

EPS (TTM)

-$1.09

P/E Ratio

-2.75

Dividend

$0.00

Beta (Volatility)

1.96 (High)

Price

$3.22

Volume

4,716,863.365

Open

$3.00

Previous Close

$3.21

Daily Range

$2.88 - $3.26

52-Week Range

$2.67 - $6.94

Estimated Earnings Date

N/A

PRME News

TMF-Pills-Purple-StockVStock.png

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

Pamela KockJun 15, 2026
Foolcom-Featured.png

PRME Revenue Misses by 73%

Motley Fool Markets TeamAug 7, 2025
Person in a lab gazing into a microscope

Why Prime Medicine Stock Was Climbing Higher This Week

Eric VolkmanMar 20, 2025
Gene therapy prime medicine 2025

Why Prime Medicine Stock Is Soaring Today

Johnny RiceMar 19, 2025
Two people seated at a lab desk featuring a PC screen and microscope

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Eric VolkmanSep 30, 2024
growth curve

2 Growth Stocks That Could Make You Richer

George Budwell, PhDAug 28, 2024
cannabis in darkness

2 Magnificent Growth Stocks With Room to Run

George Budwell, PhDMar 27, 2024
growth trend

Better Growth Stock: Archer Aviation or Prime Medicine?

George Budwell, PhDDec 19, 2023
Page 1

PRME: Motley Fool Moneyball Superscore

48

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Prime Medicine

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Industry

Biotechnology

Sector

Health Care

Employees

146

CEO

Allan Jacob Reine, MD

Website

www.primemedicine.com

PRME Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-373.29%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-36.36%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$540.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

181.38M

Volume

4.72M

Avg. Volume

3.19M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Prime Medicine Performance Analysis

Prime Medicine annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 2,983,000N/A
20252025-12-31USD 4,632,00055.3%
Prime Medicine annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.46-24.0%
20232023-12-31USD -2.1849.1%
20242024-12-31USD -1.65-24.2%
20252025-12-31USD -1.35-18.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.15

+1.0%

Gross Profit

-$0.63

+0.8%

Gross Margin

-54.68%

+0.8%

Market Cap

$540.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.56

N/A

Employees

146

N/A

Net Income

-$42.11

+0.8%

EBITDA

-$41.50

+0.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$159.93

-7.8%

Total Debt

$112.48

+0.9%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$103.51

+0.9%

Short Term Debt

$8.97

+1.2%

Return on Assets

-71.16%

+1.0%

Return on Invested Capital

-87.91%

+1.2%

Free Cash Flow

-$41.09

+1.0%

Operating Cash Flow

-$41.05

+1.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About PRME

What is the current price of Prime Medicine?

Prime Medicine is trading at $3.21 per share.

What is the 52-week range for Prime Medicine?

Over the past 52 weeks, Prime Medicine has traded between $2.67 and $6.94.

How much debt does Prime Medicine have?

As of the most recent reporting period, Prime Medicine reported total debt of $112.48M.

How much cash does Prime Medicine have on hand?

Prime Medicine reported $47.45M in cash and cash equivalents in its most recent financial results.

What is Prime Medicine’s dividend yield?

Prime Medicine does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services